The startup develops AI-powered, biomarker-guided solutions that utilize patented protein design and an automated biomarker device to enhance the targeted delivery of RNA and protein therapeutics. This technology enables precise treatment for patients by ensuring that therapies are delivered to the appropriate cells, improving therapeutic efficacy and patient outcomes.
Funding
$900K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for delivering RNA and protein therapeutics lack precision, often resulting in off-target effects and suboptimal therapeutic efficacy. This imprecision limits the potential of these therapies and can lead to adverse patient outcomes.
Solution
This startup is developing AI-driven solutions for targeted delivery of RNA and protein therapeutics, leveraging patented protein design and an automated biomarker device. The technology aims to enhance therapeutic precision by ensuring therapies are delivered specifically to the intended cells. By guiding therapeutics to the appropriate target, the platform seeks to improve efficacy, reduce off-target effects, and ultimately enhance patient outcomes. The automated biomarker device is intended to streamline the process of identifying and targeting specific biomarkers for personalized treatment.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing and delivering RNA and protein therapeutics, as well as clinicians seeking more precise and effective treatment options for their patients.
Features
- AI-powered platform for designing proteins with enhanced targeting capabilities
- Patented protein design technology for precise therapeutic delivery
- Automated biomarker device for streamlined biomarker identification
- Targeted delivery of RNA and protein therapeutics to specific cells